In a report released yesterday, Mani Foroohar from Leerink Partners maintained a Hold rating on RegenXBio (RGNX – Research Report). The company's shares closed last Monday at $33.61. According to TipRanks.com, Foroohar 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.6% and a 34.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Arrowhead Pharmaceuticals, and Adverum Biotechnologies. Currently, the analyst consensus on RegenXBio is a Moderate Buy with an average price target of $70.40, representing an 116.2% upside. In a report released yesterday, RBC Capital also reiterated a Hold rating on the stock with a $55.00 price target. See today’s analyst top recommended stocks >> The company has a one-year high of $50.26 and a one-year low of $26.40. Currently, RegenXBio has an average volume of 484.6K. Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is neutral on the stock. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD. Read More on RGNX: Cigna (CI) Receives a Hold from Leerink Partners Analysts’ Opinions Are Mixed on These Services Stocks: Universal Music Group (OtherUMGNF) and AMC Entertainment (AMC) Analysts Are Bullish on Top Conglomerates Stocks: Oshkosh (OSK), Beacon Roofing Supply (BECN) Analysts Offer Insights on Materials Companies: and Freeman Gold Corp. (FMANF) Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Dice Therapeutics Inc (DICE)